ValuEngine downgraded shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) from a sell rating to a strong sell rating in a report issued on Friday.
A number of other analysts also recently issued reports on the company. Zacks Investment Research raised Keryx Biopharmaceuticals from a sell rating to a hold rating in a research report on Monday, October 16th. Maxim Group reissued a buy rating and issued a $9.00 target price on shares of Keryx Biopharmaceuticals in a research report on Thursday, July 20th. Morgan Stanley reissued an equal weight rating and issued a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Cowen and Company reissued a market perform rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Finally, BidaskClub downgraded Keryx Biopharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 25th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $7.35.
Shares of Keryx Biopharmaceuticals (KERX) opened at $4.90 on Friday. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46. Keryx Biopharmaceuticals has a 52-week low of $4.47 and a 52-week high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.03). The business had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The business’s revenue was up 138.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) earnings per share. research analysts predict that Keryx Biopharmaceuticals will post -1.34 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “ValuEngine Lowers Keryx Biopharmaceuticals, Inc. (KERX) to Strong Sell” was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/11/14/valuengine-lowers-keryx-biopharmaceuticals-inc-kerx-to-strong-sell.html.
Several institutional investors have recently bought and sold shares of KERX. Russell Investments Group Ltd. boosted its holdings in shares of Keryx Biopharmaceuticals by 742.6% in the third quarter. Russell Investments Group Ltd. now owns 754,631 shares of the biopharmaceutical company’s stock worth $5,358,000 after acquiring an additional 665,069 shares during the period. State Street Corp boosted its holdings in shares of Keryx Biopharmaceuticals by 20.1% in the first quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock worth $21,432,000 after acquiring an additional 582,624 shares during the period. Monarch Partners Asset Management LLC bought a new position in shares of Keryx Biopharmaceuticals in the second quarter worth $3,059,000. Chicago Equity Partners LLC bought a new position in shares of Keryx Biopharmaceuticals in the second quarter worth $2,756,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 5.1% in the second quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock worth $52,043,000 after acquiring an additional 349,521 shares during the period. 65.44% of the stock is owned by hedge funds and other institutional investors.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.